More Neuroscientific Biopharmaceuticals Ltd. news
Neuroscientific Biopharmaceuticals Ltd.ASX: NSB

Successful completion of pivotal ocular safety study

Jul 1, 2021 at 12:08 AM EDT · Issued by Neuroscientific Biopharmaceuticals Ltd.

Filed with ASX · Jul 1, 2021 at 12:08 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/successful-completion-of-pivotal-ocular-safety-study

Neuroscientific Biopharmaceuticals Ltd. on 6ix

Earlier from Neuroscientific Biopharmaceuticals

  • NSB partners with Linear Research for Phase I Clinical StudyJun 22, 2021
  • R&D Tax Rebate ReceivedMay 31, 2021
  • Update on Pivotal Ocular Safety StudiesMay 4, 2021
  • Appendix 4C - quarterlyApr 29, 2021
  • Manufacturing UpdateApr 27, 2021

Later from Neuroscientific Biopharmaceuticals

  • Quarterly Update and Appendix 4CJul 30, 2021
  • Results from Pulmonary StudiesAug 18, 2021
  • Pause in TradingAug 19, 2021
  • Results from Pulmonary Studies ClarificationAug 20, 2021
  • 2021 Annual Report and Appendix 4EAug 27, 2021
All Neuroscientific Biopharmaceuticals news releases↗

Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.

Follow Neuroscientific Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer